Biosimilars

All articles by Biosimilars

Herceptin shows biosimilar markets can work. To what extent is the question.
Herceptin shows biosimilar markets can work. To what extent is the question.
Marc Iskowitz
June 9, 2023
10:11 am

Copycat versions of branded cancer drug Herceptin led to lower biologic prices, yet the real test for biosimilars lies ahead.

Amgen study: Biosimilars saved the healthcare system $21B
Amgen study: Biosimilars saved the healthcare system $21B
Jack O'Brien
October 12, 2022
2:06 pm

For biosimilars, the average sales price has decreased at a negative compound annual growth rate of -9% to -24%.

Generics, biosimilars saved the healthcare system $373B in 2021
Generics, biosimilars saved the healthcare system $373B in 2021
Lecia Bushak
September 30, 2022
2:01 pm

While the average brand name copay is more than $56, the average generic copay is just around $6.

Coronavirus isn’t the only thing on FDA’s mind
Coronavirus isn’t the only thing on FDA’s mind
Alison Kanski
April 1, 2020
5:00 am

Drugs are still being approved and reports are still churning out, all while the FDA battles the COVID-19 outbreak.

FDA clarifies biosimilar labeling, advertising guidelines
FDA clarifies biosimilar labeling, advertising guidelines
Alison Kanski
February 5, 2020
5:00 am

The FDA and FTC want to ensure companies don’t use anticompetitive practices to squash the biosimilar market.

Infographic | Global medicine spending predictions
Infographic | Global medicine spending predictions
MMM Staff
March 4, 2019
5:00 am

A recent IQVIA report breaks down global medicine spending and eyes what lies ahead.

The next five years of pharma: Pricing, biosimilars, and specialty medicines
The next five years of pharma: Pricing, biosimilars, and specialty medicines
Alison Kanski
January 29, 2019
10:11 am

A report from the IQVIA Institute for Human Data Science identified areas to watch through 2023.

Pfizer lawsuit could clear path for biosimilars
Pfizer lawsuit could clear path for biosimilars
Alison Kanski
August 23, 2018
5:00 pm

Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.

Sandoz lines up potential third-to-market Humira copy
Sandoz lines up potential third-to-market Humira copy
Laura Entis
January 17, 2018
3:00 pm

Although if approved, it’s not likely to launch in the U.S. for quite some time.

Five things for pharma marketers to know: Wednesday, January 10, 2018
Five things for pharma marketers to know: Wednesday, January 10, 2018
Virginia Lau
January 10, 2018
3:10 pm

Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict

  • From Our Partners